Health Trials

Neoadjvant Therapy

2

Review clinical trials related to Neoadjvant Therapy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma (OSCC), and to determine the safety of neoadjuvant TTP. In order to explore a better protocol of neoadjuvant therapy to improve the efficacy in patients with locally advanced OSCC.

Participants needed: 80
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Jiao Tong University School of MedicineUpdated: Nov 22, 2023Locations: 1
Eligibility criteria

Age: 18-75 years old [+10]

Unresolved grade 2 [(Common Terminology Criteria for Adverse Events (CTCAE 5.0)]... [+12]

Read more
Status: Recruiting

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS\>10 in the biopsy samples.

Participants needed: 46
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Jiao Tong University School of MedicineUpdated: Nov 22, 2023Locations: 1
Eligibility criteria

Age: 18 to 75 [+6]

Toxicity of ≥ grade 2 (CTCAE 5.0) that has not subsided due to previous anticanc... [+10]

Read more